Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

To Test or Not? Xpert MTB/RIF as an Alternative to Smear Microscopy to Guide Line Probe Assay Testing for Drug-Resistant Tuberculosis

Journal of Clinical Microbiology(2023)10.1128/jcm.00017-23Source: DataRank Database

To Test or Not? Xpert MTB/RIF as an Alternative to Smear Microscopy to Guide Line Probe Assay Testing for Drug-Resistant Tuberculosis is a research paper published in Journal of Clinical Microbiology (2023). On theSindex it has a DataRank of 0. It has been cited 1 time.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access1 citations

Download PDF

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (13 grants)Impact (FWCI 0.17)OA: hybridTopics (42)IDs (PubMed, PMC, OpenAlex)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (7)

Margaretha de Vos ORCID,Hojoon Sohn ORCID,Yonas Ghebrekristos ORCID,Tania Dolby,Robin M. Warren ORCID

Live enrichment

PubMed:37367228 PMC:PMC10358166 OpenAlex:https://openalex.org/W4382181432

National Institute of Health (NIH) USA

Grant: U54EB027049

National Institute of Health (NIH) USA

Grant: R01AI136894

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Grant: RIA2018D-2509

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Grant: PreFIT-RIA2018D-2493

EC | H2020 | ERA-LEARN | European and Developing Countries Clinical Trials Partnership

Grant: SeroSelectTB-RIA2020I-3305

National Institute of Health (NIH) USA

Grant: D43TW010350

National Institute of Health (NIH) USA

Grant: U01AI152087

European & Developing Countries Clinical Trials Partnership (EDCTP)

Grant: RIA2018D-2493

European & Developing Countries Clinical Trials Partnership (EDCTP)

Grant: RIA2020I-3305

National Institutes of Health

Grant: 5U54EB027049-05

The Center for Innovation in Point-of-Care Technologies for HIV/AIDS at Northwestern University (C-THAN)

National Institutes of Health

Grant: 1R01AI136894-01A1

Pre- and post-treatment lung microbiota, metabolome and immune signatures at the site of disease in patients with active pulmonary tuberculosis

National Institutes of Health

Grant: 5U01AI152087-03

Rapid Research for Diagnostics Development in TB Network (R2D2 TB Network)

National Institutes of Health

Grant: 5D43TW010350-02

HIV and Mycobacterial Disease in Mali

FWCI

0.17

Citation Percentile

0.5%

Citation Trend

2024

hybridLicense: cc-by

journalhttps://doi.org/10.1128/jcm.00017-23

publisherhttps://doi.org/10.1128/jcm.00017-23

publisherhttps://journals.asm.org/doi/pdf/10.1128/jcm.00017-23

repositoryhttps://pubmed.ncbi.nlm.nih.gov/37367228

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/10358166

Fields of Study

Tuberculosis Research and EpidemiologyBacterial Identification and Susceptibility TestingAntimicrobial Resistance in Staphylococcus03 medical and health sciences0302 clinical medicineHumansRifampinMycobacterium tuberculosisMicroscopyTuberculosis, Multidrug-ResistantTuberculosisSputumSensitivity and SpecificityDrug Resistance, Bacterial

MeSH Terms

HumansMicroscopyMycobacterium tuberculosisRifampinSensitivity and SpecificitySputumTuberculosisTuberculosis, Multidrug-ResistantDrug Resistance, Bacterial

Keywords

MedicineSputumTuberculosisDrug resistanceRifampicinMycobacterium tuberculosisInternal medicinePathologySurgeryMicrobiologyBiologyLine probe assayXpertMicroscopyTuberculosis, Multidrug-ResistantDrug Resistance, BacterialHumansRifampinSensitivity and Specificity

Sustainable Development Goals

SDG 0: Good health and well-being